Lexeo Therapeutics, Inc. Common Stock (LXEO) Stock Price
LXEOStock
$2.64−69.90%52W
Market Cap$216.71M
P/E—
PEG Ratio—
Div yield—
Beta1.70
LXEO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-70.33%
Price vs S&P 500 (4W)-33.97%
VGM Score21.27
LXEO Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.28 | -$0.30 | -7.69%(-$0.02) | |
| Q1 2026 | -$0.30 | -$0.25 | +16.20%(+$0.05) | |
| Q4 2025 | -$0.30 | -$0.27 | +10.47%(+$0.03) | |
| Q3 2025 | -$0.46 | -$0.33 | +28.26%(+$0.13) | |
| Q2 2025 | -$0.66 | -$0.68 | -2.45%(-$0.02) |
LXEO Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.44
4.44
4.44
4.44
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
LXEOLexeo Therapeutics, Inc. Common Stock | — | — | D | 535.2x | — | — | — | $2.64 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics is a clinical-stage biopharmaceutical company focused exclusively on developing gene therapies for hereditary and acquired genetic diseases with high unmet medical needs. The company applies genetic medicine approaches to address conditions with limited existing treatment options.